Serum HBV-DNA detection represents a new and important diagnostic tool for the hepatologist, as well as a prognostic and therapeutic guide. Though most laboratories use genomic radioactive probes, the appearance of commercially available enzyme-linked oligonucleotide probes, which simplify the method, represents an advance in HBV-DNA detection. In order to verify the value of an enzyme-linked (alkaline phosphatase) oligonucleotide probe in HBV-DNA detection, we have first compared the results of the detection of serum HBV-DNA in 46 patients at different serological stages of HBV infection using this probe and with those obtained using a genomic P32-labeled probe. Fisher's test analysis of the results shows statistical significance; this indicates a high correlation between methods. Secondly, we have tested 296 sera of patients at different serological stages of HBV infection with the enzyme-linked probe; we have found HBV-DNA in 8 patients with acute hepatitis (61.54%), 61 HBeAg (70.12%), and 7 anti-HBe (12.07%) chronic hepatitis. These results show the value of this probe for routine survey of serum HBV-DNA using a simple method which avoids the use of radioactivity.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0676.1992.tb01044.xDOI Listing

Publication Analysis

Top Keywords

serum hbv-dna
12
hbv-dna detection
12
enzyme-linked alkaline
8
alkaline phosphatase
8
phosphatase oligonucleotide
8
oligonucleotide probe
8
detection serum
8
probe hbv-dna
8
hbv-dna patients
8
patients serological
8

Similar Publications

Background: Due to the unique geographical and climatic conditions in Nagqu (Tibet), the blood station laboratory was only fully established and accredited by 2020. This study validated the performance of the laboratory's blood screening system and analyzed recent trends in blood donation and screening effectiveness.

Methods: Various serum samples were used to assess the performance of hepatitis B, hepatitis C, HIV, and syphilis tests, both serological and nucleic acid tests.

View Article and Find Full Text PDF

[Comparison of the effects of tenofovir amibufenamide and tenofovir alafenamide on lipid metabolism in the body].

Zhonghua Gan Zang Bing Za Zhi

December 2024

Department of Infectious Diseases and Hepatology, Yichun People's Hospital, Yichun336000, China.

To compare the effectiveness and safety profile of tenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF), especially the effects on lipid metabolism in the treatment of chronic hepatitis B. A retrospective study was conducted on the virological response rate, biochemical response rate, renal function indicators, and lipid metabolism status of 159 cases with chronic hepatitis B (72 cases with TMF and 87 cases with TAF) after 48 weeks of antiviral treatment. The effects of the two drugs on lipid metabolism were further explored through cell and animal experiments.

View Article and Find Full Text PDF

Serum O-glycosylated HBsAg levels correlate with HBV RNA in HBeAg positive CHB patients during antiviral therapy.

Antiviral Res

January 2025

Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address:

Background: Recent evidence has indicated that the O-glycosylated PreS2 domain of the middle HBsAg is a distinguishing characteristic that allows the identification of HBsAg of HBV Dane particles and SVPs. This study's objective was to assess the changes in serum O-glycosylated HBsAg levels in CHB patients undergoing ETV or Peg-IFNα treatment.

Methods: Our retrospective study enrolled 86 patients with genotype C CHB.

View Article and Find Full Text PDF

Development of a sandwich-type electrochemical DNA sensor based on CeO/AuPt nanoprobes for highly sensitive detection of hepatitis B virus DNA.

Bioelectrochemistry

January 2025

The Key Laboratory of Biomedical Material, School of Life Science and Technology, Xinxiang Medical University, Xinxiang 453003 China. Electronic address:

To provide accurate diagnostic evidence for early hepatitis B virus (HBV) infection-related diseases, this study targeted HBV DNA as an analyte, where a sandwich-type electrochemical DNA sensor based on gold nanoparticles/reduced graphene oxide (Au NPs/ERGO) and cerium oxide/gold-platinum nanoparticles (CeO/AuPt NPs) was constructed. Au NPs/ERGO composite nanomaterials were first synthesized on the surface of a glass carbon electrode using electrochemical co-reduction, which significantly improved the specific surface area and electrical conductivity of the electrode. Further specific hybridization of target HBV-DNA was performed by combining capture probe DNA (S1-DNA) bound to AuNPs/ERGO with CeO/AuPt modified signal probe DNA (S2-DNA).

View Article and Find Full Text PDF

Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers.

PLoS Comput Biol

January 2025

Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Quantification of intrahepatic covalently closed circular DNA (cccDNA) is a key for evaluating an elimination of hepatitis B virus (HBV) in infected patients. However, quantifying cccDNA requires invasive methods such as a liver biopsy, which makes it impractical to access the dynamics of cccDNA in patients. Although HBV RNA and HBV core-related antigens (HBcrAg) have been proposed as surrogate markers for evaluating cccDNA activity, they do not necessarily estimate the amount of cccDNA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!